AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24832482 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (EAM) derived bipolar voltage criteria
Number of subjects: 20
Study 24832482 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage cutoff <0.2 mV
Number of subjects: 20
Study 24832482 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage cutoff <0.45 mV
Number of subjects: 20
Study 24832482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar voltage cutoff of 0.27 mV on DE CMRI
Number of subjects: 20
Study 24832482 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage range 0.2-0.45 mV
Number of subjects: 20
Study 22571342 — intervention group
Group type: EXPERIMENTAL
Intervention: MG98 125 mg/m2 with Interferon-α-2β 9 MIU (continuous schedule)
Number of subjects: 0
Study 22571342 — intervention group
Group type: EXPERIMENTAL
Intervention: MG98 200 mg/m2 with Interferon-α-2β 9 MIU (intermittent schedule)
Number of subjects: 0
Study 20861218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) 43 g/d for 12 weeks
Number of subjects: 182
Study 20861218 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (CSB) 71 g/d for 12 weeks
Number of subjects: 182
Study 20861218 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 182
Study 18628466 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 173
Study 18628466 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 173
Study 16133554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g BBR three times daily for 3 months
Number of subjects: 52
Study 16133554 — intervention group
Group type: COMPARATOR
Intervention: CsA without BBR co-administration
Number of subjects: 52
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (carboplatin, etoposide, and vincristine)
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined induction and radiotherapy (HFEBRT at a dose of 72 Gy)
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (cisplatin, etoposide, cyclophosphamide, and vincristine)
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to chemotherapy
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (induction)
Number of subjects: 32
Study 12177103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (induction)
Number of subjects: 32
Study 10540010 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise to the anaerobic threshold with Bipap STD
Number of subjects: 20
Study 10540010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 7887757 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (cognitive task for 20 minutes)
Number of subjects: 44
Study 7887757 — intervention group
Group type: COMPARATOR
Intervention: Control condition (rest quietly for 20 minutes)
Number of subjects: 44
Study 1977258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A, 5 mg/kg/day for 10 days
Number of subjects: 10
Study 1977258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 10
Study 366720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Marcain
Number of subjects: 31
Study 366720 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 31
Study 31126062 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus casei variety rhamnosus; n = 42)
Number of subjects: 81
Study 31126062 — intervention group
Group type: COMPARATOR
Intervention: No probiotics (n = 39)
Number of subjects: 81
Study 27884805 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 3795
Study 26913398 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperCVAD
Number of subjects: 97
Study 26913398 — intervention group
Group type: COMPARATOR
Intervention: CHOP/CHOP-like
Number of subjects: 97
Study 23761178 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb preconditioning before induction of ischemia for surgery (tourniquet inflation)
Number of subjects: 60
Study 23761178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no limb preconditioning)
Number of subjects: 60
Study 22609217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises for 12 weeks
Number of subjects: 31
Study 22609217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates exercises)
Number of subjects: 31
Study 22609217 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 31
Study 20737165 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (240 mg) via chewing gum
Number of subjects: 9
Study 20737165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18831749 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (alcohol extract) administered for 10 days at the first sign of each common cold
Number of subjects: 90
Study 18831749 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including cranial manipulation, with up to five visits over 3 months
Number of subjects: 90
Study 16149206 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11841372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% diclofenac in 2.5% hyaluronan gel for 60 days
Number of subjects: 195
Study 11841372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% diclofenac in 2.5% hyaluronan gel for 30 days
Number of subjects: 195
Study 11841372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.5% hyaluronan gel) for 60 days
Number of subjects: 195
Study 11841372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.5% hyaluronan gel) for 30 days
Number of subjects: 195
Study 10080462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral, selective antagonist of platelet glycoprotein IIb/IIIa receptor)
Number of subjects: 90
Study 7672773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium phosphate gel (11 g five times a day)
Number of subjects: 304
Study 7672773 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg once daily for 6 weeks)
Number of subjects: 304
Study 7672773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium phosphate gel
Number of subjects: 304
Study 7672773 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 304
Study 1596776 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 40
Study 1596776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3966685 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (10 mg)
Number of subjects: 12
Study 3966685 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 30898502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic incisional negative pressure wound therapy (iNPWT)
Number of subjects: 55
Study 30898502 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative wound care
Number of subjects: 55
Study 30096637 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBI (10 min of assessment and personalized feedback)
Number of subjects: 837
Study 30096637 — intervention group
Group type: COMPARATOR
Intervention: Screening alone (control)
Number of subjects: 837
Study 27572272 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based information and skill-building program for family carers
Number of subjects: 0
Study 27572272 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 24942912 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 24942912 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18201
Study 24942912 — intervention group
Group type: COMPARATOR
Intervention: D-dimer level
Number of subjects: 18201
Study 24167223 — intervention group
Group type: COMPARATOR
Intervention: SUR group (n = 14)
Number of subjects: 26
Study 24167223 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR+EX group (n = 12)
Number of subjects: 26
Study 21367355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to a maximum of 400 mg/d for 10 weeks)
Number of subjects: 183
Study 21367355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 21367355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (in completer analysis)
Number of subjects: 183
Study 21367355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in completer analysis)
Number of subjects: 183
Study 19349934 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam dressing (Suprasorb P)
Number of subjects: 3
Study 19349934 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen dressing (Suprasorb C) plus foam dressing
Number of subjects: 3
Study 19349934 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze (control)
Number of subjects: 3
Study 18604018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal maxillary sinusitis diagnosis
Number of subjects: 100
Study 18604018 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of fungal species
Number of subjects: 100
Study 15156253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aescin and essential phospholipids (AEPL) gel
Number of subjects: 0
Study 15156253 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11839116 — intervention group
Group type: COMPARATOR
Intervention: 1 standard information session
Number of subjects: 39
Study 11839116 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 individual coping skills training sessions (once a month)
Number of subjects: 39
Study 11839116 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 group sessions (twice a month)
Number of subjects: 39
Study 9736666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (10-25 mM, 0.05-0.125 gm/dl)
Number of subjects: 32
Study 9736666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7593457 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol (50 ug/24 hrs) with periodic medroxyprogesterone (10.0 mg/day) (n = 13)
Number of subjects: 26
Study 7593457 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral estradiol (2.0 mg/day) and continuous norethisterone acetate (1.0 mg/day) (n = 13)
Number of subjects: 26
Study 2282112 — intervention group
Group type: EXPERIMENTAL
Intervention: Directing style of consultation
Number of subjects: 359
Study 2282112 — intervention group
Group type: COMPARATOR
Intervention: Sharing style of consultation
Number of subjects: 359
Study 2282112 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer consultations (both styles)
Number of subjects: 359
Study 2282112 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice consultations
Number of subjects: 359
Study 2282112 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological problems
Number of subjects: 359
Study 2282112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic problems
Number of subjects: 359
Study 7305698 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning of the EEG (feedback training)
Number of subjects: 8
Study 7305698 — intervention group
Group type: COMPARATOR
Intervention: False (noncontingent) feedback
Number of subjects: 8
Study 31455474 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh repair (Group 1)
Number of subjects: 65
Study 31455474 — intervention group
Group type: COMPARATOR
Intervention: Sublay mesh fixation technique (Group 2)
Number of subjects: 65
Study 28388994 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin <12 g/dl in women or <13 g/dl in men (anemia)
Number of subjects: 16318
Study 25879863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (75 mg/day) plus deanxit (one piece/day)
Number of subjects: 75
Study 25879863 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (75 mg/day) plus placebo (one piece/day)
Number of subjects: 75
Study 23866780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 126
Study 23866780 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 126
Study 23866780 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and placebo
Number of subjects: 126
Study 23866780 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and methylprednisolone
Number of subjects: 126
Study 23866780 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and placebo
Number of subjects: 126
Study 21463215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.3 g/kg/day, n = 51-Gln group)
Number of subjects: 101
Study 21463215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (caloreen-isocaloric, n = 50-control group)
Number of subjects: 101
Study 19640325 — intervention group
Group type: EXPERIMENTAL
Intervention: BHBH intervention (personalised lifestyle advice, goal-setting, social support)
Number of subjects: 62
Study 19640325 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 62
Study 19640325 — intervention group
Group type: EXPERIMENTAL
Intervention: BHBH intervention
Number of subjects: 62
Study 17371337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 96
Study 17371337 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 96
Study 17371337 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 96
Study 17371337 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 96
Study 17371337 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day)
Number of subjects: 96
Study 15038804 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Alliance training program
Number of subjects: 23
Study 11179160 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography of the lumbar spine
Number of subjects: 421
Study 9662766 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider referral approach to partner notification
Number of subjects: 1070
Study 9662766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of intervention
Number of subjects: 1070
Study 9662766 — intervention group
Group type: COMPARATOR
Intervention: Effectiveness comparison
Number of subjects: 1070
Study 7840516 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methotrexate followed by 5‐Fluorouracil and leucovorin rescue on day 1 (Arm A)
Number of subjects: 104
Study 7840516 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid and 5‐Fluorouracil on day 1 to 5 (Arm B)
Number of subjects: 104
Study 7840516 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders of group B)
Number of subjects: 104
Study 2205947 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 10
Study 2205947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7352844 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 0
Study 7352844 — intervention group
Group type: COMPARATOR
Intervention: Continued hospitalization
Number of subjects: 0
Study 31964367 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified OIDP scale
Number of subjects: 220
Study 30262878 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and SCI resource (n=25)
Number of subjects: 48
Study 30262878 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=23)
Number of subjects: 48
Study 28633001 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (Wingate‐based sprint interval training)
Number of subjects: 30
Study 28633001 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (high‐intensity interval training)
Number of subjects: 30
Study 28633001 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 30
Study 28633001 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT and HIIT
Number of subjects: 30
Study 26436208 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 1385
Study 26436208 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (sham-RIPC)
Number of subjects: 1385
Study 24961091 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol
Number of subjects: 54
Study 24961091 — intervention group
Group type: COMPARATOR
Intervention: 0.2% brimonidine
Number of subjects: 54
Study 24961091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of 0.5% betaxolol and 0.2% brimonidine
Number of subjects: 54
Study 21421493 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (600 µg/day) for 7 consecutive days
Number of subjects: 38
Study 21421493 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (medication and interventional therapy)
Number of subjects: 38
Study 19266831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.8 mg.kg(‐1) at 1 mg.ml(‐1) (0.8 ml.kg(‐1)) in G1 group
Number of subjects: 72
Study 19266831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.8 mg.kg(‐1) at 2 mg.ml(‐1) (0.4 ml.kg(‐1)) in G2 group
Number of subjects: 72
Study 17885570 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCET‐PI (n = 22)
Number of subjects: 41
Study 17885570 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 19)
Number of subjects: 41
Study 15466095 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 337
Study 15466095 — intervention group
Group type: COMPARATOR
Intervention: E-mail follow-up
Number of subjects: 337
Study 11719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) therapy
Number of subjects: 0
Study 11719029 — intervention group
Group type: COMPARATOR
Intervention: Control vaccinia virus (V) therapy
Number of subjects: 0
Study 11719029 — intervention group
Group type: COMPARATOR
Intervention: Observation arms from other studies (ECOG, Mayo, WHO)
Number of subjects: 0
Study 11719029 — intervention group
Group type: COMPARATOR
Intervention: ECOG and Mayo treatment arms
Number of subjects: 0
Study 9593234 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high-dose radiotherapy (5 x 5 Gy)
Number of subjects: 171
Study 9593234 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 171
Study 7874153 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte solution (C)
Number of subjects: 10
Study 7874153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal and water (M)
Number of subjects: 10
Study 3606231 — intervention group
Group type: EXPERIMENTAL
Intervention: BSHGH (0.1 mg/kg/24 h)
Number of subjects: 14
Study 29329923 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein diet
Number of subjects: 76
Study 29329923 — intervention group
Group type: EXPERIMENTAL
Intervention: 27% protein diet
Number of subjects: 76
Study 29329923 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% protein diet
Number of subjects: 76
Study 27031181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for 28 days
Number of subjects: 100
Study 27031181 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 100
Study 25742308 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 229
Study 25742308 — intervention group
Group type: COMPARATOR
Intervention: Pressure Assist/Control Ventilation
Number of subjects: 229
Study 23178468 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin administration (infused 1 day before operation and continued for 7 days after surgery)
Number of subjects: 67
Study 23178468 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin administration
Number of subjects: 67
Study 21436689 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon B/polyhexamethylene biguanide (PHMB)‐based multipurpose (MPS) solution (MPS‐1)
Number of subjects: 25
Study 21436689 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon B/polyquaternium‐1 and myristamidopropyl dimethylamine‐based solution (MPS‐2)
Number of subjects: 25
Study 21436689 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon B and another PHMB‐based solution (MPS‐3)
Number of subjects: 25
Study 21436689 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study 18227529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 2006
Study 18227529 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2006
Study 16540554 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 549
Study 12941723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg once daily for 16 weeks
Number of subjects: 54
Study 12941723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54
Study 12941723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10960381 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (administered via retrobulbar catheter)
Number of subjects: 0
Study 8977350 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for three hours)
Number of subjects: 49
Study 8977350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three sequential bolus injections followed by placebo infusion)
Number of subjects: 49
Study 1475616 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 15
Study 1475616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1475616 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive subjects
Number of subjects: 15
Study 1475616 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects
Number of subjects: 15
Study 6202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) with preoperative radiotherapy
Number of subjects: 0
Study 6202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur (FT) with preoperative radiotherapy
Number of subjects: 0